311 related articles for article (PubMed ID: 17264754)
1. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?
Han S; Roman J
Anticancer Drugs; 2007 Mar; 18(3):237-44. PubMed ID: 17264754
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.
Eucker J; Sterz J; Krebbel H; Zavrski I; Kaiser M; Zang C; Heider U; Jakob C; Elstner E; Sezer O
Anticancer Drugs; 2006 Aug; 17(7):763-9. PubMed ID: 16926626
[TBL] [Abstract][Full Text] [Related]
4. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R
Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
[TBL] [Abstract][Full Text] [Related]
5. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.
Inamoto T; Shah JB; Kamat AM
Urol Oncol; 2009; 27(6):585-91. PubMed ID: 19162510
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
[TBL] [Abstract][Full Text] [Related]
7. Mechanical loading and delta12prostaglandin J2 induce bone morphogenetic protein-2, peroxisome proliferator-activated receptor gamma-1, and bone nodule formation in an osteoblastic cell line.
Siddhivarn C; Banes A; Champagne C; Riché EL; Weerapradist W; Offenbacher S
J Periodontal Res; 2007 Oct; 42(5):383-92. PubMed ID: 17760815
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.
Theocharis S; Margeli A; Vielh P; Kouraklis G
Cancer Treat Rev; 2004 Oct; 30(6):545-54. PubMed ID: 15325034
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma in malignant diseases.
Wang T; Xu J; Yu X; Yang R; Han ZC
Crit Rev Oncol Hematol; 2006 Apr; 58(1):1-14. PubMed ID: 16388966
[TBL] [Abstract][Full Text] [Related]
10. A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplastic effect of iodine in mammary cancer.
Nuñez-Anita RE; Arroyo-Helguera O; Cajero-Juárez M; López-Bojorquez L; Aceves C
Prostaglandins Other Lipid Mediat; 2009 Jun; 89(1-2):34-42. PubMed ID: 19443248
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC).
Bren-Mattison Y; Van Putten V; Chan D; Winn R; Geraci MW; Nemenoff RA
Oncogene; 2005 Feb; 24(8):1412-22. PubMed ID: 15608671
[TBL] [Abstract][Full Text] [Related]
12. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
13. Expression of a peroxisome proliferator-activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress.
Kim HJ; Hwang JY; Kim HJ; Choi WS; Lee JH; Kim HJ; Chang KC; Nishinaka T; Yabe-Nishimura C; Seo HG
Clin Cancer Res; 2007 May; 13(9):2577-83. PubMed ID: 17473186
[TBL] [Abstract][Full Text] [Related]
14. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.
Zieleniak A; Wójcik M; Woźniak LA
Arch Immunol Ther Exp (Warsz); 2008; 56(5):331-45. PubMed ID: 18836859
[TBL] [Abstract][Full Text] [Related]
15. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis.
Margeli A; Kouraklis G; Theocharis S
Angiogenesis; 2003; 6(3):165-9. PubMed ID: 15041792
[TBL] [Abstract][Full Text] [Related]
17. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.
Desreumaux P; Ghosh S
Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():2-9. PubMed ID: 16939423
[TBL] [Abstract][Full Text] [Related]
18. Methyl 2-cyano-3,11-dioxo-18 beta-olean-1,12-dien-30-oate is a peroxisome proliferator-activated receptor-gamma agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells.
Papineni S; Chintharlapalli S; Safe S
Mol Pharmacol; 2008 Feb; 73(2):553-65. PubMed ID: 17989348
[TBL] [Abstract][Full Text] [Related]
19. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.
Sertznig P; Seifert M; Tilgen W; Reichrath J
J Cell Physiol; 2007 Jul; 212(1):1-12. PubMed ID: 17443682
[TBL] [Abstract][Full Text] [Related]
20. Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome.
Pancione M; Forte N; Sabatino L; Tomaselli E; Parente D; Febbraro A; Colantuoni V
Hum Pathol; 2009 May; 40(5):714-25. PubMed ID: 19121846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
